Sector Expert: Ram Selvaraju

H.C. Wainwright & Co.

Image: Ram Selvaraju

Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Selvaraju started in the securities industry with Rodman & Renshaw, now H.C. Wainwright, as a biotechnology equity research analyst. He was the top-ranked (#1) biotech analyst in The Wall Street Journal's "Best on the Street" survey (2006) and went on to become head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B. M., Israel's largest financial services group. While at Hapoalim, Selvaraju was regularly featured in The Wall Street Journal, Barron's, BioWorld Today, and Reuters/AP. He was also a regular guest on the Bloomberg TV program "Taking Stock," appeared with Bloomberg TV's on-air correspondents Betty Liu and Gigi Stone and was a guest on CNBC's "Street Signs with Herb Greenberg."



Recent Quotes

"INO announced its trial in advanced bladder cancer was initiated."

— Ram Selvaraju, H.C. Wainwright & Co. (10/17/17)
more >

"INO's DNA-based Zika Vaccine Phase 1 trial results demonstrate GLS-5700's potential efficacy in preventing Zika virus infection in human together with a solid safety profile."

— Ram Selvaraju, H.C. Wainwright & Co. (10/6/17)
more >

"INO announced the publication of two preclinical studies of the company's plasmid DNA-encoded monoclonal antibody constructs in treating cancer and preventing infection from a pneumonia-causing bacteria."

— Ram Selvaraju, H.C. Wainwright & Co. (9/22/17)
more >

"INO's INO-5150 generated T-cell responses in 60% of trial subjects."

— Ram Selvaraju, H.C. Wainwright & Co. (9/12/17)
more >

"INO reported top-line revenues of $20.4M in 2Q17 handily beating our original projection."

— Ram Selvaraju, H.C. Wainwright & Co. (8/9/17)
more >

"INO's pro forma cash position after the offering could be around $160M and should be sufficient for 18 months of operations; we reiterate our Buy rating."

— Ram Selvaraju, H.C. Wainwright & Co. (7/27/17)
more >

"INO announced the publication of data from a preclinical study of the company's plasmid DNA-encoded monoclonal antibody to protect against influenza infections."

— Ram Selvaraju, H.C. Wainwright & Co. (7/7/17)
more >

"VGX-3100 is the first candidate within INO's extensive pipeline to enter a pivotal study, and is the first immunotherapy and non-surgical treatment for high-grade squamous intraepithelial lesions."

— Ram Selvaraju, H.C. Wainwright & Co. (6/8/17)
more >



Due to permission requirements, not all quotes are shown.